Clinical Trials

Clinical trials provide allow researchers to gain valuable knowledge and insight in their work towards finding a cure for cancer.  At Johnston Health, we are proud to be a part of that mission. Through a agreement with Duke Oncology Network, Johnston Health is able to provide clinical research studies. Clinical trial submissions include, but are not limited to: new studies, amendments, renewals, safety letters, Investigator Drug Brochures (IDBs), advertisements, study tools, and Data and Safety Monitoring Board (DSMB) reports.

We follow strict protocol to ensure that all clinical trials protect the rights, privacy, and confidentiality of all subjects.  Johnston Health’s Research Review Committee assures the consent process and informed consent are appropriate for the subject population, and our Local Research Review Committee will confirm that all requirements of the proposed research are met.

Site specific studies available through Johnston Health are as follows:

Breast

NSABP B-47

Randomized Phase III Trial of Adjuvant Therapy comparing Chemotherapy Alone without Trastuzumab to Chemotherapy Plus Trastuzumab.

CTSU SWOG S1007

Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in patients with 1-3 positive Nodes, hormone receptor-positive and HER2-negative breast cancer with recurrence score (RS) of 25 or less.

Gastrointestinal

CALGB 80702

Phase III Trial of 6 versus 12 treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage 3 Colon Cancer.

Genitourinary

CALGB 90601

Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Bencitabine, Cisplatin, and Placebo in Pts with Advanced Transitional Cell Carcinoma.

Lung

CALGB 30607

Sunitnib as maintenance therapy, stg IIIB/IV NSCLC prev tx with combo tx (Advanced).

CALBG 30801

Phase III Double blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced NSCL Cancer.

BODE NSCLC

Prognostic validation of the BMI, airflow obstruction, dyspnea, and exercise capacity (BODE index) in Inoperable NSCLC (Advanced).

Multi-Disease Site

PHACS (Fragmin)

Prospective Randomized Multicenter Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients.

Leukemia

PROLONG OMB CELL

Phase III, Open Label, Randomized, Multicenter trial of Ofatumumab Maintenance Treatment versus no further Treatment in subjects with Relapsed Chronic Lymphocytic Leukemia (CLL) who have Responded to Induction Therapy.